Chronic lymphocytic leukemia (CLL) is a common adult leukemia caused by abnormal accumulation of B cells. Raval et al. (2007) now implicate dowregulation of the expression of the kinase DAPK1 both genetically and epigenetically in familial and sporadic CLL.
A major focus of neurodegenerative disease research is identifying the molecules and processes mediating neuronal loss. Several neurodegenerative diseases have been associated with dysfunction of a cyclin/ cyclin-dependent kinase complex cdk5/p25, including Alzheimer's disease and Parkinson's disease. Studies examining the effect of inducible overexpression of p25 have provided a functional link between cdk5/p25-associated neurodegeneration and cognitive performance (Fischer et al., 2005) . More importantly, these studies established a powerful mouse model of inducible neurodegeneration. A recent study by Fischer et al. (2007) , reported in Nature, exploits this system to ask a compelling question: does neurodegeneration result in a permanent loss of learning and memory? Remarkably, the answer is not necessarily.
As in an earlier study, Fischer et al. (2007) demonstrate that overexpression of p25 results in neurodegeneration and cognitive deficits. Moreover, chronic overexpression of p25 affects both learning and memory, mirroring the cognitive deficits observed in many dementias, including Alzheimer's disease. Surprisingly, the deficits in both learning and memory recall were completely recovered by prolonged exposure (4 weeks) to either an enriched environment or sodium butyrate, a histone deacetylase inhibitor. Recovery of cognitive performance correlated with an increase in the number of synapses, but not neurons. This last point is striking as it dissociates loss of neuronal somata with cognitive performance. Collectively, these results indicate that cognitive performance is a function of synaptic connectivity and that treatments that enhance connectivity may enhance cognitive performance.
The report by Fischer et al. (2007) stimulates many questions regarding the site of action and mechanism of the treatments that promote the recovery of cognitive function in the face of neurodegeneration. First, it would be interesting to determine whether systemic administration of sodium butyrate activated the same processes as environmental enrichment. One consequence of continual environmental enrichment is induction of increased locomotor behavior due to exploration of the novel objects placed in the rodent's environment. Thus, the effects of environmental enrichment may include an exercise component that would not be present in the animals treated with sodium butyrate. The recovery of cognitive function by either environmental enrichment or sodium butyrate was correlated with a general increase in acetylation and/or methylation of histone tails. Both environmental enrichment and systemic administration of sodium butyrate affect the entire brain, but the specific cells where changes in histone modifications occurred were not determined. This is especially important as the neurodegeneration that occurs in these mice is accompanied by apparent gliosis, the proliferation of astrocytes at sites of damage (Cruz et al., 2003) . This suggests that glia could be a target of these treatments in addition to neurons. Moreover, the changes in histone acetylation and methylation observed are consistent with increases in transcription, but the identity of the relevant genes affected by either environmental enrichment or HDAC inhibition remains to be determined. Recent evidence suggests that the transcription factor CREB is essential for HDAC inhibitor-mediated cognitive enhancement (Vecsey et al., 2007) , and a previous study suggests that environmental enrichment increases CREB immunoreactivity in the hippocampus (Williams et al., 2001) . It would be interesting to determine whether CREB and the expression of CREB target genes, such as the orphan nuclear receptor nur77, are required for the recovery of cognitive function in the mouse model used by Fischer et al. (2007) .
The study by Fischer et al. (2007) Does neuronal loss associated with dementia necessarily impair the ability to learn new information and recall old memories? In a recent report in Nature, Fischer et al. (2007) show that the ability to learn and remember can be reestablished in a mouse model of dementia through either environmental enrichment or chronic treatment with an inhibitor of histone deacetylase.
enhance cognition. In rodent models, HDAC inhibitors enhance synaptic plasticity and learning, ameliorate symptoms of Rubinstein Taybi Syndrome (a disorder characterized by mental retardation), prevent neurodegeneration associated with Huntington's disease, and act as an antidepressant (Ferrante et al., 2003; Levenson and Sweatt, 2005; Tsankova et al., 2006) . Chronic treatment with sodium butyrate significantly increased the number of synapses, suggesting that one possible effect of chronic therapy was enhanced expression of neurotrophic factors in the brain.
Restoration of memory after addition of synapses suggests two models for how environmental enrichment and sodium butyrate therapy might rescue cognitive performance. It should be noted that neither model is mutually exclusive, and it is likely that some combination of the two may have occurred in the experiments reported by Fischer et al. (2007) . First, overexpression of p25 may have selectively eliminated synapses and neurons involved in information transfer in the brain ( Figure 1A ). This could be as simple as connecting a "storage" neuron to a "conscious readout" neuron or as complex as inhibiting oscillatory behavior involved in synchronizing disparate regions of the brain. The second possibility is that overexpression of p25 results in loss of neurons involved in information storage ( Figure 1B ). For recovery to be possible, information must be distributed across a network of synapses in a highly redundant fashion, and the brain must have the ability to recapitulate the state of a network of synapses when presented with new nodes for storage. For the distributed network model to explain the data reported by Fischer et al. a critical amount of redundancy must be present before information can be consciously accessed. Disruption of the ability to access stored information or the ability to store information altogether would manifest as an inability to learn and remember, just as reported by Fischer et al.
The study by Fischer et al. represents a true breakthrough on many fronts, but perhaps the most important realization of this study is that neurodegeneration does not necessarily equate to a decline in cognitive performance. The adult brain appears to possess a degree of plasticity not previously appreciated or clinically exploited. Moreover, prevention of age-associated cognitive impairment or even recovery from traumatic brain injury or unexplained neurodegeneration might be as simple as daily enrichment of your life, or as easy as a pill.
Figure 1. Cognitive Recovery after Neurodegeneration
Shown is a simple network of neurons representing the various stages of information flow relevant to learning and memory. Information from the environment must first be received and encoded. Once encoded, the information must be stored for later recall and behavioral modification. (A) Overexpression of p25 results in loss of neurons and synapses involved in recall of previously stored information. Exposure to environmental enrichment or sodium butyrate therapy results in growth of new synapses and restoration of a critical number of synaptic connections between neurons involved in storage and recall to allow access to memories. (B) Overexpression of p25 results in loss of neurons and synapses involved in storage of information. In this model, information is stored in a highly redundant fashion at synapses across several neurons. Therefore, loss of a neuron does not result in complete loss of information. Exposure to environmental enrichment or sodium butyrate therapy results in sprouting of new synapses and restoration of access to previously stored memories.
Chronic lymphocytic leukemia (CLL) was thought to be a homogeneous disease of immature immuneincompetent B cells with minimal proliferative capacity, which accumulate because they are unable to undergo apoptosis. With increasing knowledge of the genetic lesions and signaling pathways involved, CLL is now considered a more heterogeneous leukemia that originates from antigen-stimulated B cells that escape normal cell death mechanisms and/or undergo increased proliferation (Chiorazzi et al., 2005) due to aberrant activity of ZAP70, a Src family protein tyrosine kinase normally only expressed in T cells. Interestingly, CLL is a familial disease in a relatively high proportion (10%-20%) of patients indicating an underlying genetic susceptibility for developing malignant lymphoproliferation. However, genome-wide screening of families with CLL has not identified clear candidate genes (Sellick et al., 2006) .
Epigenetic regulation of gene expression-which is crucial for both normal and malignant development of cells-has been implicated in CLL (Calin et al., 2005) . Epigenetics affects all aspects of tumor cell biology including cell growth, cell cycle control, differentiation, DNA repair, apoptosis, and cell death. Epigenetic regulation by, for example, promoter methylation, microRNAs, or histone modifications not only influences expression of individual genes but also may affect whole cellular programs such as hematopoietic differentiation (Chen et al., 2004) . Consequently, epigenetic modulation of gene expression has become a target for therapeutic intervention (Bhalla, 2005) .
In this issue of Cell, a consortium led by Christoph Plass and Albert de la Chapelle presents results from their search to find genes involved in aberrant cellular proliferation, differentiation, and apoptosis in CLL (Raval et al., 2007) . They identified DAP kinase 1 (DAPK1) as a candidate gene silenced in all cases of CLL. Epigenetic silencing of DAPK through promoter methylation occurred in almost all sporadic cases of CLL. Furthermore, in a large family with several affected individuals, a mutation/polymorphism in the promoter of DAPK1 was identified as causing persistent downregulation of DAPK1 expression due to increased binding of the HOXB7 transcriptional repressor. This study identifies a single gene as being affected by genetic and epigenetic alterations in each case of CLL analyzed and provides evidence for the genetic susceptibility of this disease.
Several functions for DAPK1 in differentiation and cell death have been described (Bialik and Kimchi, 2006) . Initially, DAPK was cloned as a serine/threonine kinase associated with the cytoskeleton and identified as a mediator of cell death induced by interferon γ. DAPK1 is
